Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Antibodies that block programmed death 1 (PD-1) protein improve survival in patients with advanced non-small-cell lung cancer (NSCLC) but have not been tested in resectable NSCLC, a condition in which little progress has been made during the past decade. METHODS: In this pilot study, we administered two preoperative doses of PD-1 inhibitor nivolumab in adults with untreated, surgically resectable early (stage I, II, or IIIA) NSCLC. Nivolumab (at a dose of 3 mg per kilogram of body weight) was administered intravenously every 2 weeks, with surgery planned approximately 4 weeks after the first dose. The primary end points of the study were safety and feasibility. We also evaluated the tumor pathological response, expression of programmed death ligand 1 (PD-L1), mutational burden, and mutation-associated, neoantigen-specific T-cell responses. RESULTS: Neoadjuvant nivolumab had an acceptable side-effect profile and was not associated with delays in surgery. Of the 21 tumors that were removed, 20 were completely resected. A major pathological response occurred in 9 of 20 resected tumors (45%). Responses occurred in both PD-L1-positive and PD-L1-negative tumors. There was a significant correlation between the pathological response and the pretreatment tumor mutational burden. The number of T-cell clones that were found in both the tumor and peripheral blood increased systemically after PD-1 blockade in eight of nine patients who were evaluated. Mutation-associated, neoantigen-specific T-cell clones from a primary tumor with a complete response on pathological assessment rapidly expanded in peripheral blood at 2 to 4 weeks after treatment; some of these clones were not detected before the administration of nivolumab. CONCLUSIONS: Neoadjuvant nivolumab was associated with few side effects, did not delay surgery, and induced a major pathological response in 45% of resected tumors. The tumor mutational burden was predictive of the pathological response to PD-1 blockade. Treatment induced expansion of mutation-associated, neoantigen-specific T-cell clones in peripheral blood. (Funded by Cancer Research Institute-Stand Up 2 Cancer and others; ClinicalTrials.gov number, NCT02259621 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies examining the clinical activity of single agent anti-PD-1/PD-L1 therapies in the neoadjuvant setting have reported MPR rates between 19% and 45% in patients with resectable NSCLC14–16.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some studies have found that high TCR diversity in peripheral blood and tumors prior to ICI therapy is predictive of effective treatment, others have pointed to ICI therapy-associated increases in TCR clonality, that is, enrichment of T cells with the same TCRs, as a sign of effective therapy (150, 157-161).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [160]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immune checkpoint blockade (ICB), especially targeting the inhibitory receptor programmed cell death 1 (PD-1) expressed on CD8+ T cells, is a highly effective immunotherapy for various cancers.”
From Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“Similarly, studies of neoadjuvant immunotherapy in patients with resectable NSCLC reported responses irrespective of PD-L114,21,”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [14]
In the citing paper
“Clinical trials with ICT in the neoadjuvant setting have now demonstrated clinical benefit in multiple tumor types, including melanoma (173, 174), Merkel cell carcinoma (175), NSCLC (176), MMRdeficient colorectal cancer (177), urothelial carcinoma (21, 178), and breast cancer (179-181).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [176]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationToxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cited by
Items 501–600 of 1,000
Zheng, S., & Tao, W. (2021) · Cancers · doi:10.3390/cancers13051013 · Cited by 44
Liu, X., Sun, W., Wu, J., Feng, Y., Mao, L., Chen, M., Yang, X., Wang, H., Chi, K., Yang, Y., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00871-1 · Cited by 38
Self-citationImmunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives
Luo, W., Wang, Z., Zhang, T., Yang, L., Xian, J., Li, Y., & Li, W. (2021) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbab027 · Cited by 44
Wang, S., Yuan, P., Mao, B., Li, N., Ying, J., Tao, X., Tang, W., Zhang, L., Geng, X., Zhang, F., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-021-00244-6 · Cited by 42
Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC
Friedlaender, A., Naidoo, J., Banna, G. L., Metro, G., Forde, P. M., & Addeo, A. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102350 · Cited by 44
Self-citationImmunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm
Berghmans, T., Dingemans, A. C., Hendriks, L. E. L., & Cadranel, J. L. (2020) · European Respiratory Journal · doi:10.1183/13993003.01907-2019 · Cited by 38
Sun, C., Liu, Y., Zhang, P., Wang, X., Xu, Y., Lin, X., Ma, X., Guo, Y., Qiu, S., Shao, G., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03896-w · Cited by 41
“Accordingly, Forde (Forde et al. 2018) reported that nine out of 20 (45%) resected tumors achieved MPR through neoadjuvant nivolumab, with a recurrence-free survival rate within 18 months of 73%.”
BackgroundInfluentialWu, Y., Verma, V., Gay, C. M., Chen, Y., Liang, F., Lin, Q., Wang, J., Zhang, W., Hui, Z., Zhao, M., et al. (2023) · Cancer · doi:10.1002/cncr.34755 · Cited by 50
The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer
Dunne, E. G., Fick, C. N., Isbell, J. M., Chaft, J. E., Altorki, N. K., Park, B. J., Spicer, J. D., Forde, P. M., Gomez, D. R., Iyengar, P., et al. (2024) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2024.01.024 · Cited by 45
Self-citationImmune Checkpoint Blockade across the Cancer Care Continuum
Helmink, B. A., Gaudreau, P.-O., & Wargo, J. A. (2018) · Immunity · doi:10.1016/j.immuni.2018.06.003 · Cited by 41
Gastman, B., Agarwal, P. K., Berger, A., Boland, G. M., Broderick, S., Butterfield, L. H., Byrd, D. R., Fecci, P. E., Ferris, R. L., Fong, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001583 · Cited by 40
Self-citationHasegawa, H., Shitara, K., Takiguchi, S., Takiguchi, N., Ito, S., Kochi, M., Horinouchi, H., Kinoshita, T., Yoshikawa, T., Muro, K., et al. (2022) · Gastric Cancer · doi:10.1007/s10120-022-01286-w · Cited by 39
“Because no prior information was available regarding efficacy of nivolumab monotherapy for resectable GC, we referred to the favorable results in the previous trial for NSCLC [14] and determined the duration of neoadjuvant treatment to be relatively short at 4 weeks.”
BackgroundMethodResultInfluentialNeoadjuvant Immunotherapy in Melanoma: The Paradigm Shift
Hieken, T. J., Kreidieh, F., Aedo-Lopez, V., Block, M. S., McArthur, G. A., & Amaria, R. N. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390614 · Cited by 43
Cheng, Y., Chen, Z., Huang, J.-J., & Shao, D. (2023) · European Radiology · doi:10.1007/s00330-023-09922-4 · Cited by 40
“The latest studies have shown that the major pathological response (MPR) to neoadjuvant nivolumab [12] and atezolizumab [13] in resectable NSCLC were 45% and 21%, respectively, and the adverse reactions were controllable without increasing the surgical deaths.”
BackgroundHouda, I., Dickhoff, C., Groot, C. A. U., Reguart, N., Provencio, M., Lévy, A., Dziadziuszko, R., Pompili, C., Maïo, M. D., Thomas, M., et al. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.100840 · Cited by 49
Cao, L., Zhong, N., Chen, Y., Li, Z., Wang, G.-R., Xiao, Y., Liu, X.-H., Jia, J., Liu, B., & Bu, L. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217095 · Cited by 40
Wang, Q., Wu, Y., Jiang, G., & Huang, X. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03124-6 · Cited by 41
“Immune checkpoint blockade (ICB) therapy has demonstrated efficiency in various cancers, including non-small cell lung cancer (NSCLC) [4], metastatic melanoma [5] and renal cancer [6].”
BackgroundImmunotherapy in patients with early stage resectable nonsmall cell lung cancer
Ghysen, K., & Vansteenkiste, J. (2018) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000497 · Cited by 36
PD-1 Blockade in Early-Stage Lung Cancer
Rosner, S., Reuss, J. E., & Forde, P. M. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-050217-025205 · Cited by 39
Self-citationYu, Y., Zheng, P., Gao, L., Li, H., Tao, P., Dengfeng, W., Ding, F., Shi, Q., & Chen, H. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000346 · Cited by 41
2020 Innovation-Based Optimism for Lung Cancer Outcomes
Schenk, E. L., Patil, T., Pacheco, J. M., & Bunn, P. A. (2020) · The Oncologist · doi:10.1002/onco.13590 · Cited by 40
Zhou, C., Feng, M., Chen, X., Gao, Y., Chen, L., Li, L., Li, D., & Cao, Y. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s286274 · Cited by 41
“However, the recurrence and mortality rates of LUAD are still high, and the prognosis of patients is poor.(8,9) Considering the low survival rate and poor status of LUAD patients, it is imperative to find more effective biomarkers to facilitate novel therapeutic methods.”
BackgroundThelen, M., Wennhold, K., Lehmann, J. M., Garcia-Marquez, M. A., Klein, S., Kochen, E., Lohneis, P., Lechner, A., Wagener‐Ryczek, S., Plum, P. S., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00196-x · Cited by 38
Nenclares, P., Rullan, A., Tam, K., Dunn, L. A., John, M. A. S., & Harrington, K. J. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351336 · Cited by 47
Feng, Z., Chen, Y., Cai, C., Tan, J., Liu, P., Chen, Y., Shen, H., Zeng, S., & Han, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.916594 · Cited by 62
Chiang, C., Chiang, C., Sheng‐Kai, K., Hsia, Y. P., Lee, Y.-W., Wu, H., Chiang, C., Peng, C.-Y., Wei, J. C., Shiah, H., et al. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac150 · Cited by 39
Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial
Coutzac, C., Bibeau, F., Abdelghani, M. B., Aparicio, T., Cohen, R., Coquan, E., Dubreuil, O., Evesque, L., Ghiringhelli, F., Kim, S. C. H., et al. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.07.008 · Cited by 38
Đačić, S., Travis, W. D., Giltnane, J. M., Kos, F., Abel, J., Hilz, S., Fujimoto, J., Sholl, L. M., Ritter, J. M., Khalil, F. K., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.12.010 · Cited by 41
Self-citationKim, C. G., Hong, M. H., Kim, D., Lee, B. H., Kim, H., Ock, C., Kelly, G., Bang, Y. J., Kim, G., Lee, J. E., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3249 · Cited by 38
Reijers, I. L. M., Menzies, A. M., López‐Yurda, M., Versluis, J. M., Rozeman, E. A., Saw, R. P. M., van Houdt, W. J., Kapiteijn, E., van der Veldt, A. A. M., Suijkerbuijk, K. P. M., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115141 · Cited by 38
The role and therapeutic implications of T cells in cancer of the lung
Neeve, S. A., Robinson, B. W. S., & Fear, V. S. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1076 · Cited by 39
“In the neoadjuvant setting, a recent clinical trial for nivolumab, in resectable NSCLC patients, determined a major pathological response in 45% of patients (n = 21).(58) Further, they also observed expansion of previously undetectable neoantigen-specific T cells, perhaps suggestive of priming of de novo immune respon…”
BackgroundZhang, Z., Cheng, S., Gong, J., Lu, M. S., Zhou, J., Zhang, X., Li, J., Shen, L., & Peng, Z. (2020) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2020.06.034 · Cited by 36
Zhang, Q., Wu, L., Liu, S., Chen, Q., Zeng, L., Chen, X., & Zhang, Q. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01613-0 · Cited by 35
“Removal of malignant tumors through surgery has been considered as the best treatment option for NSCLC, which promoted long-term response and survival for about 30% of the patients [3, 4].”
BackgroundSintilimab for the treatment of non-small cell lung cancer
Zhang, L., Lin, W., Tan, F., Li, N., Xue, Q., Gao, S., Gao, Y., & He, J. (2022) · Biomarker Research · doi:10.1186/s40364-022-00363-7 · Cited by 39
“(overall MPR rate of 45%, without surgery delay) [70].”
BackgroundMarinelli, D., Gallina, F. T., Pannunzio, S., Civita, M. A. D., Torchia, A., Giusti, R., Gelibter, A. J., Roberto, M., Verrico, M., Melis, E., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104190 · Cited by 42
Self-citationYang, M., Li, X., Cai, C., Liu, C., Ma, M., Qu, W., Zhong, S., Zheng, E., Zhu, H., Jin, F., et al. (2023) · European Radiology · doi:10.1007/s00330-023-10503-8 · Cited by 43
“Substantial evidences recently emerged on the safety and effectiveness of neoadjuvant chemoimmunotherapy [1– 4].”
Immune escape of head and neck cancer mediated by the impaired MHC-I antigen presentation pathway
Luo, X., Qiu, Y., Fitzsimonds, Z. R., Wang, Q., Chen, Q., & Lei, Y. L. (2024) · Oncogene · doi:10.1038/s41388-023-02912-2 · Cited by 37
“Immune checkpoint inhibitors (ICIs) have obtained signi fi cant success in the treatment of lung cancer and melanoma in recent clinical trials [7 – 9], however, a much lower response has been found in recurrent and advanced HNSCC [10].”
Yang, Z., Wang, S., Yang, H., Jiang, Y., Zhu, L., Zheng, B., Fu, H., Ma, J., Xie, H., Wang, Z., et al. (2024) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2024.02.006 · Cited by 40
Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers
Tan, P. B., Verschoor, Y. L., van den Berg, J. G., Balduzzi, S., Kok, N. F. M., Ijsselsteijn, M. E., Moore, K., Jurdi, A. A., Tin, A., Kaptein, P., et al. (2025) · Nature · doi:10.1038/s41586-025-09679-4 · Cited by 42
Advances in theranostic biomarkers for tumor immunotherapy
Bellesœur, A., Torossian, N., Amigorena, S., & Romano, E. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.02.005 · Cited by 35
Kaseda, K. (2020) · Diagnostics · doi:10.3390/diagnostics10080561 · Cited by 39
Zeng, J., Yang, X., Li, Y., Li, W., & Zheng, Y. (2020) · Respiratory Research · doi:10.1186/s12931-020-01587-7 · Cited by 38
Immunotherapy for the treatment of colorectal cancer
Lumish, M. A., & Cercek, A. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26357 · Cited by 38
“Increased peripheral blood TCR clonality following ICI treatment is associated with longer PFS,(81,83) and the sum proportion of TCR clones shared between the tumor and peripheral blood following ICI has been shown to correlate with pathologic response.(12) Increased baseline TCR diversity may explain the unprecedente…”
ResultNeoadjuvant Chemotherapy for Colon Cancer
Roth, M., & Eng, C. (2020) · Cancers · doi:10.3390/cancers12092368 · Cited by 40
Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot
Janjigian, Y. Y., Wolchok, J. D., & Ariyan, C. E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.013 · Cited by 35
Self-citationJin, P., Li, J., Meng, Y., Wu, L., Bai, M., Yu, J., & Meng, X. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.028 · Cited by 35
Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
Soh, J., Hamada, A., Fujino, T., & Mitsudomi, T. (2021) · Cancers · doi:10.3390/cancers13164035 · Cited by 38
“5 45 15 Median RFS: NR 18mRFS: 73% On going [35]”
Yang, C., Zhang, Z., Tang, X., Zhang, X., Chen, Y., Hu, T., Zhang, H., Guan, M., Zhang, X., & Wu, Z. (2021) · Human Cell · doi:10.1007/s13577-021-00630-z · Cited by 38
Lung cancer mortality in Europe and the USA between 2000 and 2017: an observational analysis
Jani, C., Marshall, D. C., Singh, H., Goodall, R. J., Shalhoub, J., Omari, O. A., Salciccioli, J. D., & Thomson, C. C. (2021) · ERJ Open Research · doi:10.1183/23120541.00311-2021 · Cited by 37
The Role of NcRNAs to Regulate Immune Checkpoints in Cancer
Jiang, Y., Zhao, L., Wu, Y., Deng, S., Cao, P., Lei, X., & Yang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.853480 · Cited by 35
Learning from the nexus of autoimmunity and cancer
Mangani, D., Yang, D., & Anderson, A. C. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.022 · Cited by 33
An integrative pan-cancer analysis of COPB1 based on data mining
Chen, H., Li, K., Li, Y., Xie, P., He, J., & Zhang, H. (2020) · Cancer Biomarkers · doi:10.3233/cbm-200398 · Cited by 33
“Additionally, the expression level of PD-L1 was limited in predicting the efficacy of immunocheckpoint inhibitors [31].”
Ryu, R. J., & Ward, K. E. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00277 · Cited by 34
“In a recent small study, neoadjuvant nivolumab resulted in ≤10% viable tumor in 45% of patients with resectable stage I-III NSCLC (n = 20) (27).”
BackgroundFassan, M., Cavallin, F., Guzzardo, V., Kotsafti, A., Scarpa, M., Cagol, M., Chiarion‐Sileni, V., Saadeh, L. M., Alfieri, R., Castagliuolo, I., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2359 · Cited by 33
Xie, D., Sun, Q., Wang, X., Zhou, J., Fan, J., Ren, Z., & Gao, Q. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-7037 · Cited by 47
“Neoadjuvant PD-1 blockade by enhancing both the local and systemic antitumor immune response is suggested as an efficacious approach in resectable lung cancer or recurrent glioblatoma (22,23).”
BackgroundCabezas-Camarero, S., & Pérez‐Segura, P. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103569 · Cited by 33
Ahmed, J., Das, B., Shin, S. J., & Chen, A. P. (2023) · Cancers · doi:10.3390/cancers15245841 · Cited by 44
“Studies have indicated predictability in anticipating responses to ICIs in neoadjuvant or early-stage scenarios across various cancer types, including but not limited to NSCLC, melanoma, breast cancer, and HNSCC [106,150–152].”
BackgroundZhang, Z., Chen, X., Gao, S., Fang, X., & Ren, S. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00935-9 · Cited by 42
“So far, evidence has justified the clinical benefit of ICI, ACT, and other immunotherapies in provoking an anti-tumor immune response to control cancer progression and metastasis [2, 3].”
BackgroundYang, H. J., Jin, T., Li, M., Xue, J., & Lü, B. (2019) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbz004 · Cited by 38
“The latest clinical trial NCT02259621 reported use of neoadjuvant nivolumab (anti-PD-1inhibitor) in resectable NSCLC patients (stages I, II and III).(51) The first dose of nivolumab was given to the patients about 4 weeks before the planned surgery.”
BackgroundRe-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis
Hasson, S. P., Salwen, B., Sivan, A., Shamai, S., Geva, R., Merimsky, O., Raphael, A., Shmilovich, H., Moshkovits, Y., Kapusta, L., et al. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01648-3 · Cited by 34
Principles of Immunotherapy in Non-Small Cell Lung Cancer
Hsu, M. L., & Naidoo, J. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.009 · Cited by 34
Self-citationLaparoscopic Liver Resection for Intrahepatic Cholangiocarcinoma: A Single-Center Experience
Haber, P. K., Wabitsch, S., Kästner, A., Andreou, A., Krenzien, F., Schöning, W., Pratschke, J., & Schmelzle, M. (2020) · Journal of Laparoendoscopic & Advanced Surgical Techniques · doi:10.1089/lap.2020.0215 · Cited by 32
Wu, F., Li, W., Zhao, W., Zhou, F., Xie, H., Shi, J., Yu, G., Fan, J., Jiang, T., & Zhou, C. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.149 · Cited by 35
Driving the Improvement of Lung Cancer Prognosis
Liang, W., Liu, J., & He, J. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.008 · Cited by 32
Wu, C., Rao, X., & Lin, W. L. (2020) · Cancer Medicine · doi:10.1002/cam4.3655 · Cited by 34
Glatzer, M., Leskow, P., Caparrotti, F., Eliçin, O., Furrer, M., Gambazzi, F., Dutly, A., Gelpke, H., Gückenberger, M., Heuberger, J., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1210 · Cited by 35
“Interestingly only two patients had a radiologic partial response (41).”
BackgroundAffolter, A., Lammert, A., Kern, J., Scherl, C., & Rotter, N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.666515 · Cited by 36
Liberini, V., Mariniello, A., Righi, L., Capozza, M., Delcuratolo, M. D., Terreno, E., Farsad, M., Volante, M., Novello, S., & Deandreis, D. (2021) · Cancers · doi:10.3390/cancers13184543 · Cited by 36
“Notably, the T cell clones occurring at a higher frequency after surgery were shared between the blood and tissue, and many of these clones were not detected in the peripheral blood before treatment, suggesting that ICIs may induce the expansion of specific T cell clones [84].”
Kothari, A. N., White, M. G., Peacock, O., Kaur, H., Palmquist, S. M., You, N., Taggart, M. W., Salem, U. I., Overman, M. J., Kopetz, S., et al. (2022) · British journal of surgery · doi:10.1093/bjs/znac050 · Cited by 34
Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133
Pacheco, J. M., & Bunn, P. A. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.12.019 · Cited by 32
Cascone, T., Sepesi, B., Lin, H. Y., Kalhor, N., Parra, E. R., Jiang, M., Godoy, M. C. B., Zhang, J., Fossella, F. V., Tsao, A. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4180 · Cited by 31
“In the first reported study 477 of 21 patients (stage IB-IIIA) treated with two doses of nivolumab followed by surgery, authors 478 observed a MPR of 45% (9/20) with a radiographic response rate of only 10% (2/21) (29).”
BackgroundSelf-citationEerkens, A. L., Brummel, K., Vledder, A., Paijens, S. T., Requesens, M., Loiero, D., van Rooij, N., Plat, A., Haan, F.-J., Klok, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52098-8 · Cited by 35
Organoids as models of immune-organ interaction
Harter, M. F., Recaldin, T., & Gjorevski, N. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116214 · Cited by 35
Ahern, E. S., Cubitt, A., Ballard, E. L., Teng, M. W. L., Dougall, W. C., Smyth, M. J., Godbolt, D., Naidoo, R., Goldrick, A., & Hughes, B. G. M. (2019) · Trials · doi:10.1186/s13063-019-3951-x · Cited by 33
Chan, H. Y., Zhang, J., Garliss, C. C., Kwaa, A. K., Blankson, J. N., & Smith, K. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00591 · Cited by 34
Self-citationMitchell, K. G., Amini, B., Wang, Y., Carter, B. W., Godoy, M. C. B., Parra, E. R., Behrens, C., Villalobos, P. A., Reuben, A., Lee, J. J., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02560-5 · Cited by 34
Umeda, Y., Morikawa, M., Anzai, M., Ameshima, S., Kadowaki, M., Waseda, Y., Shigemi, H., Tsujikawa, T., Kiyono, Y., Okazawa, H., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000349 · Cited by 34
“Therefore, it is important to discriminate between ‘metabolic’ pseudoprogression and authentic disease progression when increased 18 F-FDG uptake in the lesion is observed after nivolumab treatment.”
BackgroundYou, W., Shang, B., Sun, J., Liu, X., Su, L., & Jiang, S. (2020) · Oncology Reports · doi:10.3892/or.2020.7643 · Cited by 36
“Consistently, a pilot study of nivolumab in early-stage NSCLC revealed a significantly higher mean TMB in tumors with a major pathological response compared with tumors without a major pathological response (68).”
BackgroundCurrent status of cancer immunotherapy for gynecologic malignancies
Nishio, H., Iwata, T., & Aoki, D. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa214 · Cited by 31
Lee, C., DiNatale, R. G., Chowell, D., Krishna, C., Makarov, V., Valero, C., Vuong, L. H., Lee, M., Weiss, K. L., Hoen, D., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0053 · Cited by 36
Improvement of Pulmonary Photodynamic Therapy: Nebulisation of Curcumin-Loaded Tetraether Liposomes
Lehmann, J., Agel, M. R., Engelhardt, K. H., Pinnapireddy, S. R., Agel, S., Duse, L., Preis, E., Wojcik, M., & Bakowsky, U. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081243 · Cited by 31
“One of the basic problems in cancer therapy is the high rate of side effects due to undesired tissue destruction and a loss of anatomical and physiological integrity [5].”
BackgroundNeoadjuvant immunotherapy in gastrointestinal cancers – The new standard of care?
Petričević, B., Kabiljo, J., Zirnbauer, R., Walczak, H., Laengle, J., & Bergmann, M. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.015 · Cited by 32
Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery
Marron, T. U., Galsky, M. D., Taouli, B., Fiel, M. I., Ward, S., Kim, E., Yankelevitz, D., Doroshow, D., Guttman-Yassky, E., Ungar, B., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01681-x · Cited by 30
How I treat MSI cancers with advanced disease
Kok, M., Chalabi, M., & Haanen, J. B. A. G. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000511 · Cited by 39
Iivanainen, S., & Koivunen, J. P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020556 · Cited by 30
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma
Rocha, P., Salazar, R., Zhang, J., Ledesma, D. A., Solórzano, J. L., Mino, B., Villalobos, P. A., Dejima, H., Duose, D. Y., Diao, L., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02820-4 · Cited by 33
“Recent studies have shed light on the clinical value of immunotherapy for earlier stage lung tumors including in the neoadjuvant and adjuvant settings [6, 7].”
BackgroundSelf-citationWeissferdt, A., Pataer, A., Swisher, S. G., Heymach, J. V., Gibbons, D. L., Cascone, T., & Sepesi, B. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.02.014 · Cited by 34
Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer
Isaacs, J., & Stinchcombe, T. E. (2022) · Drugs · doi:10.1007/s40265-022-01721-3 · Cited by 41
“[25] 22 I–IIIA Nivolumab Safety and feasibility 10 45”
BackgroundZhang, B., Xiao, Q., Xiao, H., Wu, J., Yang, D., Tang, J., Li, X., Wu, Z., Zhou, Y., & Wang, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.858189 · Cited by 34
“The extent of this effect is heterogeneous and unpredictable from restaging imaging prior to surgery (2, 3).”
BackgroundXiong, J., Barayan, R., Louie, A. V., & Lok, B. H. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.07.008 · Cited by 35
Mitchell, K. G., Parra, E. R., Nelson, D. B., Zhang, J., Wistuba, I. I., Fujimoto, J., Roth, J. A., Antonoff, M. B., Corsini, E. M., Vaporciyan, A. A., et al. (2019) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2019.04.084 · Cited by 34
Self-citationNeoadjuvant therapy in non-small cell lung cancer: basis, promise, and challenges
Kalvapudi, S., Vedire, Y., Yendamuri, S., & Barbi, J. J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1286104 · Cited by 35
“MPR is de fi ned as less than or equal to 10% residual tumor cells in resected lung and lymph node tissue (48).”
BackgroundInfluentialPreclinical development and clinical studies of targeted JAK/STAT combined Anti-PD-1/PD-L1 therapy
Chen, M., & Wang, S.-L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111717 · Cited by 30
Yi, M., Li, T., Niu, M., Wu, Y., Zhao, B., Shen, Z., Hu, S., Zhang, C. H., Zhang, X., Zhang, J., et al. (2024) · Advanced Science · doi:10.1002/advs.202408598 · Cited by 40
Self-citationInamura, K., Shigematsu, Y., Ninomiya, H., Nakashima, Y., Kobayashi, M., Saito, H., Takahashi, K., Futaya, E., Okumura, S., Ishikawa, Y., et al. (2018) · Cancers · doi:10.3390/cancers10080252 · Cited by 33
Chen, R., Lee, W., Fujimoto, J., Li, J., Hu, X., Mehran, R. J., Rice, D. C., Swisher, S. G., Sepesi, B., Tran, H. T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1767 · Cited by 32
“Moreover, although immune 424 checkpoint blockade (ICB) targeting T cells have revolutionized the therapeutic 425 landscape across many different cancer types (40-46), the response rates to single 426 agent ICB treatment was only 9%-30% in MPM patients (47-51).”
BackgroundSelf-citationPrognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis
Eichhorn, F., Kriegsmann, M., Klotz, L. V., Kriegsmann, K., Muley, T., Zgorzelski, C., Christopoulos, P., Winter, H., & Eichhorn, M. (2021) · Cancers · doi:10.3390/cancers13092046 · Cited by 30
“A paradigm shift in early lung cancer treatment is of current interest, as the first promising results on adjuvant anti-PD1/-PDL1 therapy upfront surgery have been reported [12,13].”
BackgroundNeoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
Chen, Y., Yan, B., Xu, F., Hui, Z., Zhao, G., Liu, J., Zhang, H., Zeng, Z., Zhang, R., Provencio, M., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-329 · Cited by 30
“As we all knows that single chemotherapy or immune therapy in NSCLC is with lower effective rate and low survival rate; the pCR rate and MPR rate are very low (1-3).”
BackgroundMethodInfluentialLü, Y., Ng, A. H. C., Chow, F. E., Everson, R. G., Helmink, B. A., Tetzlaff, M. T., Thakur, R., Wargo, J. A., Cloughesy, T. F., Prins, R. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24293-4 · Cited by 30
Daly, M. E. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01611 · Cited by 34
Metadata
- Authors
- Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., Battafarano, R. J., Velez, M. J., Rekhtman, N., Olah, Z., Naidoo, J., Marrone, K. A., Verde, F., Guo, H., Zhang, J., Caushi, J. X., Chan, H. Y., Sidhom, J.-W., Scharpf, R. B., White, J., Gabrielson, E., Wang, H., Rosner, G. L., Rusch, V., Wolchok, J. D., Merghoub, T., Taube, J. M., Velculescu, V. E., Topalian, S. L., Brahmer, J. R., & Pardoll, D. M.
- Affiliations
- Johns Hopkins University (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Forde, Patrick M.
- Chaft, Jamie E.
- Smith, Kellie N.
- Anagnostou, Valsamo
- Cottrell, Tricia R.
- Hellmann, Matthew D.
- Zahurak, Marianna
- Yang, Stephen C.
- Jones, David R.
- Broderick, Stephen
- Velez, Moises J.
- Rekhtman, Natasha
- Naidoo, Jarushka
- Marrone, Kristen A.
- Verde, Franco
- Guo, Haidan
- Zhang, Jiajia
- Caushi, Justina X.
- Sidhom, John-William
- Scharpf, Robert B.
- White, James
- Wang, Hao
- Rosner, Gary L.
- Rusch, Valerie
- Wolchok, Jedd D.
- Merghoub, Taha
- Taube, Janis M.
- Velculescu, Victor E.
- Topalian, Suzanne L.
- Brahmer, Julie R.
- Pardoll, Drew M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-24
- Volume
- 378
- Issue
- 21
- Pages
- 1976-1986
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6223617
- OpenAlex
- W2798160602
- Cited by
- 2,099
- References
- 33
- Citations by year
- 2026: 123 · 2025: 181 · 2024: 241 · 2023: 304 · 2022: 304 · 2021: 342 · 2020: 279 · 2019: 214 · 2018: 110
- FWCI
- 89.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- International Association for the Study of Lung Cancer
- LUNGevity Foundation
- MacMillan Foundation
- Lung Cancer Foundation of America
- National Cancer Institute (CA006973, CA121113, CA180950, CA193145, P30 CA006973, P30 CA008748, R01 CA142779, T32 CA193145)
- ECOG-ACRIN
- Commonwealth Foundation
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Bristol-Myers Squibb
- Bloomberg–Kimmel Institute for Cancer Immunotherapy
- Stand Up To Cancer (SU2C-AACR-DT1012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- neoadjuvant immunotherapy, anti-PD-1 therapy, nivolumab, resectable non-small cell lung cancer, early-stage lung cancer, pathological response, PD-L1 expression, tumor mutational burden, predictive biomarkers, treatment safety and feasibility
- MeSH terms
- Nivolumab, Adenocarcinoma, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Biopsy, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Pilot Projects, Neoadjuvant Therapy, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.